Skip to content
Screener

Amgen AMGN Other Non-Current Assets

Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
$7.48B+20.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.31B
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$11.24M+108%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$103K0.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$2.36M+55.5%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$94.7M-18.7%

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$220.64B+44.0%
Enterprise value$277.37B+32.8%
P/E25.2×+2.1×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000318154-26-000126
Line itemJune 30, 2026December 31, 2025
Property, plant and equipment, net8,5477,913
Intangible assets, net20,48722,276
Goodwill18,66818,680
Other noncurrent assets12,97612,660
Total assets$95,639$90,586
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$2,865$2,367

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's other non-current assets?
Amgen (AMGN) reported other non-current assets of $12.98B in Q2 2026.
How has Amgen's other non-current assets changed year-over-year?
Amgen's other non-current assets increased by 17.7% year-over-year, from $11.02B to $12.98B.
What is the long-term trend for Amgen's other non-current assets?
Over 5 years (2020 to 2025), Amgen's other non-current assets has grown at a 17.6% compound annual growth rate (CAGR), from $5.64B to $12.66B.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Amgen's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude